Top

International Urology and Nephrology

Published in:

01-04-2019 | Prostate Cancer | Urology - Original Paper

Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among Caucasians and African Americans treated by surgery or radiation

Authors: Mohamed H. Kamel, Milan Bimali, Mahmoud I. Khalil, Ehab Eltahawy, LJoseph Su, Nabil K. Bissada, Rodney Davis

Published in: International Urology and Nephrology | Issue 4/2019

Abstract

Purpose

To study regional trends in average years of potential life lost (AYPLL) among Caucasians (CA) and African Americans (AA) with prostate cancer (Pca) who received radical prostatectomy or radiation therapy among four different regions in the US as well as across different tumor grades. Years of potential life lost is defined as the difference between a predetermined end-point age and the age at death for a death that occurred prior to that end age, hence the AYPLL is calculated by dividing the total YPLL by the total number of patients died.

Methods

The surveillance epidemiology and end results (SEER) database was used to identify Pca patients who were CA or AA and who have received radical prostatectomy or radiation therapy. Study duration was divided into four decades; 1973–1982 (D1), 1983–1992 (D2), 1993–2002 (D3), 2003–2012 (D4). Examined regions were; North East (NE), North central (NC), South and West. Tumor grade was classified into; well/moderately differentiated (WD/MD) and poorly/undifferentiated (PD/UD) groups. Differences in AYPLL among CA and AA in each of these variables were compared.

Results

Overall, compared to CA, AA were diagnosed and died earlier from Pca. AA had higher AYPLL to Pca than CA. In both tumor grade groups, progressive increase in AYPLL among AA compared to CA was noted over the last three decades. In the WD/MD group, except for the South region, the highest recorded difference in AYPLL between AA and CA was in D4. In the PD/UD group, a similar difference in AYPLL between AA and CA was noted in all regions. The difference in AYPLL was higher in the PD/UD group than the WD/MD group.

Conclusions

Racial disparity between AA and CA existed across the examined regions. It is more pronounced in advanced tumor grades. The differences were more significant in the last decade.

Available only for authorised users

https://seer.cancer.gov/statfacts/html/prost.html

https://www.cdc.gov/cancer/dcpc/data/geographic.htm

Wagner SE, Bauer SE, Bayakly AR, Vena JE (2013) Prostate cancer incidence and tumor severity in Georgia: descriptive epidemiology, racial disparity, and geographic trends. Cancer Causes Control: CCC 24(1):153–166. https://doi.org/10.1007/s10552-012-0101-0 CrossRefPubMed

Xiao H, Warrick C, Huang Y (2009) Prostate cancer treatment patterns among racial/ethnic groups in Florida. J Natl Med Assoc 101(9):936–943CrossRefPubMed

https://www.cdc.gov/mmwr/preview/mmwrhtml/00001773.htm

Li C, Ekwueme DU, Rim SH, Tangka FK (2010) Years of potential life lost and productivity losses from male urogenital cancer deaths–United States, 2004. Urology 76(3):528–535. https://doi.org/10.1016/j.urology.2010.04.030 CrossRefPubMed

Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP (2005) Years of life lost (YLL) from cancer is an important measure of population burden–and should be considered when allocating research funds. Br J Cancer 92(2):241–245. https://doi.org/10.1038/sj.bjc.6602321 CrossRefPubMedPubMedCentral

https://seer.cancer.gov/registries/data.html

Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME (2016) The surveillance, epidemiology, and end results (SEER) program and pathology: toward Strengthening the critical relationship. Am J Surg Pathol 40(12):e94–e102. https://doi.org/10.1097/PAS.0000000000000749 CrossRefPubMedPubMedCentral

10.

Wu XC, Yu Q, Andrews PA, Ranganath P, Qiao B, Ajani U, Wohler B, Zhang Z (2010) Comparisons of directly coded SEER Summary Stage 2000 and collaborative staging derived SEER summary stage 2000. J Regist Manag 37(4):137–140

11.

Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL (2010) Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol 184(6):2303–2307. https://doi.org/10.1016/j.juro.2010.08.017 CrossRefPubMedPubMedCentral

12.

Kochanek KD, Xu J, Murphy SL, Minino AM, Kung HC (2011) Deaths: final data for 2009. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl Vital Stat Syst 60(3):1–116

13.

Kamel MH, Moore PC, Bissada NK, Heshmat SM (2012) Potential years of life lost due to urogenital cancer in the United States: trends from 1972 to 2006 based on data from the SEER database. J Urol 187(3):868–871. https://doi.org/10.1016/j.juro.2011.10.142 CrossRefPubMed

14.

Han Y, Rand KA, Hazelett DJ, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Schumacher FR, Berndt SI, Wang Z, Xu J, Rohland N, Reich D, Tandon A, Pasaniuc B, Allen A, Quinque D, Mallick S, Notani D, Rosenfeld MG, Jayani RS, Kolb S, Gapstur SM, Stevens VL, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJM, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Witte JS, Casey G, Lubwama A, Pooler LC, Sheng X, Coetzee GA, Cook MB, Chanock SJ, Stram DO, Watya S, Blot WJ, Conti DV, Henderson BE, Haiman CA (2016) Prostate cancer susceptibility in men of african ancestry at 8q24. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv431 CrossRefPubMedPubMedCentral

15.

Powell IJ, Bock CH, Ruterbusch JJ, Sakr W (2010) Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 183(5):1792–1796. https://doi.org/10.1016/j.juro.2010.01.015 CrossRefPubMed

16.

Schreiber D, Levy EB, Schwartz D, Rineer J, Wong A, Rotman M, Weiss JP (2014) Impact of race in a predominantly African-American population of patients with low/intermediate risk prostate cancer undergoing radical prostatectomy within an equal access care institution. Int Urol Nephrol 46(10):1941–1946. https://doi.org/10.1007/s11255-014-0773-3 CrossRefPubMed

17.

Lee DJ, Consedine NS, Gonzalez JR, Spencer BA (2012) Association of healthcare barriers with prostate-specific antigen screening among African-American and Afro-Caribbean men. Urology 80(3):556–563. https://doi.org/10.1016/j.urology.2012.02.085 CrossRefPubMed

18.

Barocas DA, Grubb R III, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED (2013) Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer 119(12):2223–2229. https://doi.org/10.1002/cncr.28042 CrossRefPubMed

19.

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D’Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL (2014) Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 84(2):386–392. https://doi.org/10.1016/j.urology.2014.05.009 CrossRefPubMed

20.

Xu J, Janisse J, Ruterbusch J, Ager J, Schwartz KL (2016) Racial differences in treatment decision-making for men with clinically localized prostate cancer: a population-based study. J Racial Ethn Health Dispar 3(1):35–45. https://doi.org/10.1007/s40615-015-0109-8 CrossRef

21.

Wong AT, Safdieh JJ, Rineer J, Weiner J, Schwartz D, Schreiber D (2015) A population-based analysis of contemporary patterns of care in younger men (< 60 years old) with localized prostate cancer. Int Urol Nephrol 47(10):1629–1634. https://doi.org/10.1007/s11255-015-1096-8 CrossRefPubMed

22.

Chu DI, Moreira DM, Gerber L, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ (2012) Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 118(20):4999–5007. https://doi.org/10.1002/cncr.27456 CrossRefPubMed

23.

Daskivich TJ, Kwan L, Dash A, Litwin MS (2015) Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system. Prostate Cancer Prostatic Dis 18(2):104–109. https://doi.org/10.1038/pcan.2014.51 CrossRefPubMed

24.

Tyson MD, Andrews PE, Etzioni DA, Ferrigni RG, Humphreys MR, Swanson SK, Castle EK (2013) Marital status and prostate cancer outcomes. Can J Urol 20(2):6702–6706PubMed

25.

White A, Coker AL, Du XL, Eggleston KS, Williams M (2011) Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas. Cancer 117(5):1080–1088. https://doi.org/10.1002/cncr.25671 CrossRefPubMed

26.

Moschini M, Carroll PR, Eggener SE, Epstein JI, Graefen M, Montironi R, Parker C (2017) Low-risk prostate cancer: identification, management, and outcomes. Eur Urol 72(2):238–249. https://doi.org/10.1016/j.eururo.2017.03.009 CrossRefPubMed

27.

Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR (2002) Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 168(6):2510–2515. https://doi.org/10.1097/01.ju.0000036493.19691.e0 CrossRefPubMed

28.

Chen Y-W, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL (2016) Association between treatment at a high-volume facility and improved survival for radiation-treated men with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 94(4):683–690. https://doi.org/10.1016/j.ijrobp.2015.12.008 CrossRefPubMed

29.

Moses KA, Orom H, Brasel A, Gaddy J, Underwood W III (2016) Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer. Urol Oncol 34(9):415. https://doi.org/10.1016/j.urolonc.2016.04.002. (e412–415, e417)CrossRefPubMedPubMedCentral

30.

Wang C, Raldow A, King CR, Kupelian PA, Nickols N, Chang AJ, Steinberg ML, Spratt DE, Nguyen PL, Kishan AU (2018) Racial disparity in androgen deprivation therapy utilization for men with high-risk prostate cancer treated with intensity-modulated radiation therapy in the modern era—a SEER-medicare linked database analysis. Int J Radiat Oncol Biol Phys 102(3):e147–e148. https://doi.org/10.1016/j.ijrobp.2018.07.286 CrossRef

31.

Trinh Q-D, Sun M, Sammon J, Bianchi M, Sukumar S, Ghani KR, Jeong W, Dabaja A, Shariat SF, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI (2012) Disparities in access to care at high-volume institutions for uro-oncologic procedures. Cancer 118(18):4421–4426. https://doi.org/10.1002/cncr.27440 doiCrossRefPubMed

32.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schroder FH, Roobol MJ (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110(11):1672–1677. https://doi.org/10.1111/j.1464-410X.2012.11434.x CrossRefPubMed

33.

Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C (2001) Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 93(3):219–225CrossRefPubMed

34.

Qi R, Moul J (2017) African American men with low-risk prostate cancer are candidates for active surveillance: the will-rogers effect? Am J Men Health 11(6):1765–1771. https://doi.org/10.1177/1557988317721107 CrossRef

35.

Schreiber D, Chhabra A, Rineer J, Weedon J, Schwartz D (2015) A population-based study of men with low-volume low-risk prostate cancer: does African-American race predict for more aggressive disease? Clin Genitourin Cancer 13(4):e259–e264. https://doi.org/10.1016/j.clgc.2015.02.006 CrossRefPubMed

36.

Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR (2016) Pathological and biochemical outcomes among African-American and Caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy. J Urol 196(5):1408–1414. https://doi.org/10.1016/j.juro.2016.06.086 CrossRefPubMedPubMedCentral

37.

Dosemeci M, Hoover RN, Blair A, Figgs LW, Devesa S, Grauman D, Fraumeni JF Jr (1994) Farming and prostate cancer among African-Americans in the southeastern United States. J Natl Cancer Inst 86(22):1718–1719CrossRefPubMed

38.

Blair A, Fraumeni JF (1978) Geographic patterns of prostate cancer in the United States. J Natl Cancer Inst 61(6):1379–1384PubMed

39.

Meliker JR, Goovaerts P, Jacquez GM, Avruskin GA, Copeland G (2009) Breast and prostate cancer survival in Michigan: can geographic analyses assist in understanding racial disparities? Cancer 115(10):2212–2221. https://doi.org/10.1002/cncr.24251 CrossRefPubMed

40.

Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA (2014) Plasma vitamin D and prostate cancer risk: results from the selenium and Vitamin E cancer prevention trial. Cancer Epidemiol Biomarkers Prev 23(8):1494–1504. https://doi.org/10.1158/1055-9965.EPI-14-0115 CrossRefPubMedPubMedCentral

41.

Reinstatler L, Carmichael D, Austin AM, Goodney PP, Bynum JP, Hyams ES (2018) Regional variation in the intensity of prostate cancer care: a study of a large medicare sample. Int J Urol 25(11):974–975. https://doi.org/10.1111/iju.13775 CrossRefPubMed

42.

Moses KA, Orom H, Brasel A, Gaddy J, Underwood W III (2017) Racial/ethnic disparity in treatment for prostate cancer. Does cancer severity matter? Urology 99:76–83. https://doi.org/10.1016/j.urology.2016.07.045 CrossRefPubMed

Title: Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among Caucasians and African Americans treated by surgery or radiation
Authors: Mohamed H. Kamel
Milan Bimali
Mahmoud I. Khalil
Ehab Eltahawy
LJoseph Su
Nabil K. Bissada
Rodney Davis
Publication date: 01-04-2019
Publisher: Springer Netherlands
Keywords: Prostate Cancer
Prostate Cancer
Published in: International Urology and Nephrology / Issue 4/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02116-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among Caucasians and African Americans treated by surgery or radiation

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

ALLN-177, oral enzyme therapy for hyperoxaluria

Pentoxifylline for the prevention of contrast-induced nephropathy in diabetic patients undergoing angioplasty: a randomized controlled trial

Uroflow stop test with electromyography: a novel index of urinary continence recovery after RARP

Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes

ISPD guideline-driven retraining, exit site care and decreased peritonitis: a single-center experience in Israel

Defining a clinically significant struvite stone: a non-randomized retrospective study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page